Reiner Gentz is the Chief Scientific Officer at FAB Biopharma, with over 25 years of expertise in protein development, cGMP manufacturing, and regulatory compliance. He holds a PhD in Molecular Biology from the University of Heidelberg and has a distinguished career developing therapeutic proteins, antibodies, and vaccines. Reiner has held senior positions at Human Genome Sciences and Roche, and founded Gentz Biopharmaceutical Consulting LLC. He has played key roles in developing groundbreaking biologics, including the first FDA-approved drug for lupus, Benlysta®, and has extensive experience designing advanced biopharmaceutical facilities.